Nidovirales | Jotup

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on:

Tuesday, March 2, 2021

Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points:

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on:

Tuesday, March 2, 2021

Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points:

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

Retrieved on:

Thursday, February 4, 2021

Coronaviridae, Nidovirales, Sarbecovirus, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus, Human coronavirus 229E, Middle East respiratory syndrome–related coronavirus

An additional panel has been included containing epitopes of high genetic homology to endemic human coronaviruses (HCoV).

Key Points:

An additional panel has been included containing epitopes of high genetic homology to endemic human coronaviruses (HCoV).
This panel will facilitate research into the role HCoV play in the immune response to SARS-CoV-2 infection.
A recent report on health care workers in the US demonstrated cross-reactive T cell responses between HCoV and SARS-CoV-2 infections1.
T-SPOT, T-Cell Xtend, the Oxford Immunotec logo, and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.

BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies To Live COVID-19 Virus

Retrieved on:

Tuesday, February 2, 2021

Sarbecovirus, Zoonoses, Animal diseases, Nidovirales, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus disease, COVID-19 vaccine, Reporter virus particles

It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.

Key Points:

It's worth noting that OSU is one of the few institutions that has the laboratory capability to study live SARS-CoV-2 virus.
Plaques are produced by infection of cultured human cells by a live SARS-CoV-2 virus.
For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus

Retrieved on:

Wednesday, January 20, 2021

Health, Infectious diseases, Genetics, Research, Science, Biotechnology, Sarbecovirus, Nidovirales, Zoonoses, Animal diseases, Severe acute respiratory syndrome coronavirus 2, GISAID, Severe acute respiratory syndrome coronavirus, Qiagen, Severe acute respiratory syndrome, Severe acute respiratory syndrome–related coronavirus

QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020.

Key Points:

QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020.
A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2.
As a virus encoded by RNA nucleotides, SARS-CoV-2 frequently mutates due to erroneous or ineffective replication of the virus genome.
These mutations can sometimes produce viruses with altered properties or even entirely new strains.

Studies Reveal Potential Weaknesses in SARS-CoV-2 Infection

Retrieved on:

Thursday, December 10, 2020

Coronaviridae, Sarbecovirus, Zoonoses, Nidovirales, Coronavirus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Draft:COVID-19 pandemic in Pakistan, Antibody-dependent enhancement

Published in the journal Cell online Dec. 9, the studies revealed that TMEM41B was essential for SARS-CoV-2 to replicate.

Key Points:

Published in the journal Cell online Dec. 9, the studies revealed that TMEM41B was essential for SARS-CoV-2 to replicate.
They also compared how it reproduces in infected cells to three other seasonal coronaviruses known to cause the common cold.
"Together, our studies represent the first evidence of transmembrane protein 41 B as a critical factor for infection by flaviviruses and, remarkably, for coronaviruses, such as SARS-CoV-2, as well," says the studies' co-senior investigator John T. Poirier, PhD.
"Comparing a newly discovered virus to other known viruses can reveal shared liabilities, which we hope serve as a catalogue of potential vulnerabilities for future outbreaks."

CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies

Retrieved on:

Tuesday, December 1, 2020

The animals were therapeutically treated with CEL-SCIs LEAPS COV-19 peptides one day after infection with a lethal dose of SARS-CoV-2.

Key Points:

The animals were therapeutically treated with CEL-SCIs LEAPS COV-19 peptides one day after infection with a lethal dose of SARS-CoV-2.
We are highly encouraged by these results, which clearly show our LEAPS COV-19 peptides produced a survival benefit in a very credible animal model, which mimics the virus effects in humans.
A critical benefit of LEAPSs mechanism of action is its focus on highly conserved portions within the nucleoprotein of the virus.
Our next step is to leverage the findings from these two animal studies into future studies that will optimize treatment dosing and test additional LEAPS peptides as a therapy.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Retrieved on:

Thursday, October 15, 2020

Coronaviridae, Sarbecovirus, Zoonoses, Nidovirales, Respiratory diseases, Bat virome, Animal virology, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Zoonosis, Coronavirus disease, Coronavirus

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points:

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
"'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Retrieved on:

Thursday, October 15, 2020

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points:

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
"'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Global Severe Acute Respiratory Syndrome (SARS) Pipeline Review 2020: Therapeutics Development, Therapeutics Assessment, Companies Involved, Dormant Projects - ResearchAndMarkets.com

Retrieved on:

Monday, October 5, 2020

Health, Infectious diseases, Respiratory diseases, Sarbecovirus, Bat virome, Severe acute respiratory syndrome, Nidovirales, Health, SARS outbreak, Zoonoses, Book:Pandemic, Coronavirus disease

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

Key Points:

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.
The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.